Eton Pharmaceuticals (ETON) Non-Current Debt (2019 - 2025)

Eton Pharmaceuticals (ETON) has 7 years of Non-Current Debt data on file, last reported at $21.8 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt fell 26.98% year-over-year to $21.8 million; the trailing twelve-month figure through Dec 2025 stood at $21.8 million (down 26.98% YoY), and the FY2025 full-year result was $21.8 million, down 26.98% from the prior year.
• Non-Current Debt eased to $21.8 million in Q4 2025, from $27.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $30.0 million in Q1 2025 to a low of $4.2 million in Q3 2023.
• A 5-year average of $12.3 million and a median of $5.9 million in 2021 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 35.3% in 2021 and fell 26.98% in 2025, its largest moves.
• Tracing ETON's Non-Current Debt over 5 years: stood at $5.3 million in 2021, then climbed by 2.32% to $5.4 million in 2022, then dropped by 22.05% to $4.2 million in 2023, then jumped by 610.29% to $29.8 million in 2024, then decreased by 26.98% to $21.8 million in 2025.
• Business Quant data shows ETON's Non-Current Debt at $21.8 million in Q4 2025, $27.6 million in Q3 2025, and $27.4 million in Q2 2025.